Radotinib

DRUG4 trials

Conditions

Bone Marrow DiseasesChronic Myeloid LeukemiaChronic Myeloid Leukemia, Chronic PhaseHematologic DiseasesLeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidPhiladelphia Chromosome

Phase 1

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

CompletedNCT01602952

Il-Yang Pharm. Co., Ltd.Hematologic Diseases, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive +2

Start: 2008-07-31End: 2018-07-13Updated: 2018-08-29

Phase 2

Radotinib as 3rd or Later Line Therapy in CP-CML

NCT02422719

Ulsan University HospitalChronic Myeloid Leukemia

Start: 2015-04-30End: 2019-03-31Target: 73Updated: 2016-05-11

Phase 3

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

CompletedNCT01511289

Il-Yang Pharm. Co., Ltd.Bone Marrow Diseases, Hematologic Diseases, Leukemia +3

Start: 2011-08-31Updated: 2016-02-24

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Active, not recruitingNCT03722420

Il-Yang Pharm. Co., Ltd.Chronic Myeloid Leukemia, Chronic Phase

Start: 2018-12-28End: 2027-12-31Target: 238Updated: 2026-09-03

Related Papers

Clinical pharmacokinetic characteristics and the food effect of radotinib.

2026-03-27

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood2018-11-29

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Clinical Cancer Research2017-09-2274 citations